Literature DB >> 4510179

Hodgkin's disease. A clinico-pathological study of 250 cases with a 5-year follow-up.

K A Newton, D H Mackenzie, M F Spittle, A Mikolajczuk.   

Abstract

Two hundred and fifty cases of histologically proven Hodgkin's disease have been reviewed. These cases were classified according to the Rye Conference histological classification (Lukes et al., 1966a) and according to the Cross classification (Cross, 1969). Overall, both classifications were reasonably effective in predicting prognosis but that of Cross with its seven sub-groups proved more difficult to use than the simpler Rye classification. In all cases the follow-up period exceeded 5 years. A study was made of the influence of clinical symptoms on survival with particular reference to night sweats, fever, pruritus, anorexia, lassitude, weight loss, haematological abnormalities and splenic enlargement. The presence of these abnormalities adversely affected prognosis. The spread of the disease from one group of nodes to the next was also documented. Considering all cases the 5-year survival was 54%. The 5-year survivals according to histological type were: lymphocytic predominance 69%, nodular sclerosis 57%, mixed cellularity 41%, lymphocytic depletion 40%. The 10-year survival was 23% which, when corrected by the actuarial method (Berkson and Gage, 1950), rose to 36%. The importance of symptomatology as well as histological grading in the prognosis of Hodgkin's disease is confirmed.

Entities:  

Mesh:

Year:  1973        PMID: 4510179      PMCID: PMC2008821          DOI: 10.1038/bjc.1973.10

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  A study of Hodgkin's disease treated by irradiation.

Authors:  M V PETERS; K C MIDDLEMISS
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1958-01

2.  Calculation of survival rates for cancer.

Authors:  J BERKSON; R P GAGE
Journal:  Proc Staff Meet Mayo Clin       Date:  1950-05-24

3.  Factors influencing survival in patients with Hodgkin's disease.

Authors:  D W Smithers
Journal:  Clin Radiol       Date:  1969-04       Impact factor: 2.350

4.  Report of the Committee on Hodgkin's Disease Staging Procedures.

Authors:  S A Rosenberg; M Boiron; V T DeVita; R E Johnson; B J Lee; J E Ultmann; M Viamonte
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

5.  A clinicopathological study of nodular sclerosing Hodgkin's disease.

Authors:  R M Cross
Journal:  J Clin Pathol       Date:  1968-05       Impact factor: 3.411

6.  Preliminary experience with total nodal irradiation in Hodgkin's disease.

Authors:  R E Johnson; L B Thomas; M Schneiderman; D W Glenn; F Faw; M D Hafermann
Journal:  Radiology       Date:  1970-09       Impact factor: 11.105

7.  Interrelations of the histologic types of Hodgkin's disease.

Authors:  S B Strum; H Rappaport
Journal:  Arch Pathol       Date:  1971-02

8.  Prognostic factors in localized Hodgkin's disease treated with regional radiation. Clinical presentation and specific histology.

Authors:  L M Fuller; J F Gamble; C C Shullenberger; J J Butler; E A Gehan
Journal:  Radiology       Date:  1971-03       Impact factor: 11.105

9.  Evidence for an orderly progression in the spread of Hodgkin's disease.

Authors:  S A Rosenberg; H S Kaplan
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

10.  Histologic classification of Hodgkin's disease.

Authors:  K O Franssila; T V Kalima; A Voutlainen
Journal:  Cancer       Date:  1967-10       Impact factor: 6.860

View more
  3 in total

1.  Editorial: Fever in malignant disease.

Authors: 
Journal:  Br Med J       Date:  1974-03-30

2.  Hodgkin's disease in children: clinico-roentgenologic features of the lesion in the chest.

Authors:  B A Kolygin; A G Vesnin
Journal:  Pediatr Radiol       Date:  1976-04-14

Review 3.  Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review.

Authors:  J C Underwood
Journal:  Br J Cancer       Date:  1974-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.